| Literature DB >> 34322937 |
Rajeevalochana Parthasarathy1, Milly Mathew1, Priyanka Koshy2, Madhusri Babu1, Georgi Abraham1.
Abstract
Acute interstitial nephritis can result due to exposure to any medication, toxins, infections or malignancy. In the midst of this Coronavirus (COVID-19) pandemic, there has been a race for finding remedies to prevent the spread of and control the complications due to Severe Acute Respiratory Syndrome Coronavirus 2. Certain Indian medicinal herb concoctions like kabasura kudineer and nilavembu kudineer are being widely publicized to boost immunity and reduce the risk of developing COVID-19. Little knowledge exists about the adverse effects of these herbal remedies. We report two patients who presented to us with vague complaints following the ingestion of kabasura kudineer and we diagnosed them with acute tubulointerstitial nephritis (ATIN). The temporal relationship of ingestion of these remedies to the development of ATIN calls for vigilance and caution with regular monitoring of renal functions especially in those with chronic kidney disease.Entities:
Keywords: COVID-19; acute kidney injury (AKI); herbal medications
Mesh:
Substances:
Year: 2021 PMID: 34322937 PMCID: PMC8420558 DOI: 10.1111/nep.13947
Source DB: PubMed Journal: Nephrology (Carlton) ISSN: 1320-5358 Impact factor: 2.358
FIGURE 1(A) Interstitial inflammation with tubular injury and WBC cast (H&E). (B) Tubular injury with neutrophilc tubulitis and WBC cast; interstitial edema and inflammation (H&E)
Clinical characteristics of the patients
| Name | Mr. K | Mr. D |
| Age | 51 years | 63 years |
| Gender | Male | Male |
| Base line serum creatinine [SCr (mg/dl)] | 1.21 mg/dl in January 2020 | Not available |
| Diabetes mellitus | No | No |
| Systemic hypertension | No | No |
| Others | S/P. Aortic valve replacement (January/2013) | None |
| Medications | Warfarin and metoprolol | None |
| Urine routine | Albumin‐nil, sugar‐nil, pus cells 3–5, epithelial cells 1–2, RBC 10–15, granular cast present | Albumin‐nil, sugar‐nil, Pus cells >50, epithelial cells 2–3, RBC 3–5, WBC cast and granular cast present |
| Haemoglobin (g/dl) | 12.9 | 7.2 |
| Total leucocyte count (cells/mm3) | 18 300 | 8900 |
| Platelet (Lak/mm3) | 3.00 | 3.18 |
| Urea (mg/dl) | 29 | 74 |
| SCr at presentation (mg/dl) | 3.56 | 3.25 |
| Sodium (mmol/L) | 138 | 124 |
| Potassium (mmol/L) | 3.47 | 2.89 |
| Bicarbonate (mmol/L) | 29 | 30 |
| Calcium (mg/dl) | 8.6 | 8.4 |
| Phosphorous (mg/dl) | 3.2 | 4.4 |
| T. protein (g/dl) | 10.3 | 6.5 |
| Albumin (g/dl) | 4.7 | 3.4 |
| TSH (mIU/L) | 3.22 | 1.95 |
| HbA1c (%) | 5.6 (23 December 2019) | 6.3 |
|
Oro pharyngeal Swab for RT‐PCR COVID | Negative | Negative |
| Kidney biopsy Findings |
Acute tubulointerstitial nephritis Mild to moderate Arteriosclerosis Interstitial fibrosis and tubular atrophy 10%–15% |
Acute tubulointerstitial nephritis IgA nephropathy Interstitial fibrosis and tubular atrophy 5%–10% |
| Immunofluorescence | Negative for IgA, IgG, C3, Kappa and Lambda | IgA (2+), C3 (Trace), Lambda (2+) and Kappa (Trace) |
| Treatment given | Prednisone 0.5 mg/kg bodyweight/day tapered over 8 weeks | Prednisone 0.5 mg/kg bodyweight/day tapered over 6 weeks |
| SCr (mg/dl) after 2 weeks of treatment with steroids | 1.49 | 2.23 |
| SCr (mg/dl) on further follow up | 1.2 mg/dl after 3 months | 1.1 mg/dl after 2 months |
| Side effects of treatment | Hyperglycemia needing medications | Hyperglycemia needing medications |